Movement disorders : official journal of the Movement Disorder Society Journal

Overview
Identity
View All

publication venue for

Small Strokes, Big Impact: Excessive Mortality After Acute Ischemic Stroke in Parkinson's Disease. 2026
Increase of Plasma Biomarkers in Friedreich's Ataxia: Potential Insights into Disease Pathology.. 40:1863-1873. 2025
Copy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells.. 40:950-961. 2025
Epigenetic and Metabolic Landscape of Dementia with Lewy Bodies.. 40:490-501. 2024
Calcitriol in Friedreich Ataxia.. 39:1653-1654. 2024
Research Priorities on the Role of α-Synuclein in Parkinson's Disease Pathogenesis.. 39:1663-1678. 2024
Optimizing Screening for Intrastriatal Interventions in Huntington's Disease Using Predictive Models.. 39:855-862. 2024
Blocking the Self-Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition.. 39:644-650. 2024
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.. 38:2269-2281. 2023
Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease.. 38:1483-1492. 2023
Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.. 38:1541-1545. 2023
Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".. 38:1127-1142. 2023
Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease.. 38:1262-1272. 2023
Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.. 38:1363-1364. 2023
A Novel Metric for Predicting Severity of Disease Features in Friedreich's Ataxia.. 38:970-977. 2023
Why Therapeutic Trials Fail in Primary Tauopathies.. 38:545-550. 2023
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.. 38:453-463. 2023
It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.. 38:342-347. 2022
Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.. 38:313-320. 2022
Nicotine-Mediated Rescue of α-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.. 38:244-255. 2022
Rehabilitating Cough Dysfunction in Parkinson's Disease: A Randomized Controlled Trial.. 38:201-211. 2022
Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.. 37:1904-1914. 2022
Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine.. 37:1749-1755. 2022
Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology.. 37:1505-1515. 2022
Physician-Assisted Dying: Access and Utilization in Patients with Movement Disorders.. 37:694-698. 2022
Repeat RNA Toxicity Drives Ribosomal RNA Processing Defects in SCA2.. 36:2464-2467. 2021
Impaired Pre-Motor Circuit Activity and Movement in a Drosophila Model of KCNMA1-Linked Dyskinesia.. 36:1158-1169. 2021
Consensus Guidelines on Rodent Models of Restless Legs Syndrome.. 36:558-569. 2020
Is Levodopa Response a Valid Indicator of Parkinson's Disease?. 36:948-954. 2020
Reply to: Diagnostic Delay in Cervical Dystonia-Dystonia With Antecedent ET?. 35:1086-1087. 2020
Progressive Supranuclear Palsy and Statin Use.. 35:1253-1257. 2020
If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?. 35:1727-1730. 2020
Cervical dystonia incidence and diagnostic delay in a multiethnic population.. 35:450-456. 2019
The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration.. 34:959-969. 2019
Lifestyle and Parkinson's disease progression.. 34:7-8. 2019
Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women.. 33:1492-1496. 2018
Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.. 33:414-420. 2018
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.. 32:319-324. 2017
Dietary antioxidants and Parkinson's disease.. 32:1501-1503. 2017
Aducanumab reduces Aβ plaques in Alzheimer's disease.. 31:-. 2016
The best medicine? The influence of physical activity and inactivity on Parkinson's disease.. 31:1444-1454. 2016
Intake of antioxidant vitamins and risk of Parkinson's disease.. 31:1909-1914. 2016
Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.. 31:417-21. 2016
The NINDS Parkinson's disease biomarkers program.. 31:915-23. 2015
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.. 31:95-102. 2015
Educational attainment and motor burden in Parkinson's disease.. 30:1143-7. 2015
Cognitive profile of LRRK2-related Parkinson's disease.. 30:728-33. 2015
Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease.. 29:827-30. 2014
A randomized controlled trial of patient-reported outcomes with tai chi exercise in Parkinson's disease.. 29:539-45. 2013
Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease.. 28:302-10. 2013
Caffeine consumption and risk of dyskinesia in CALM-PD.. 28:380-3. 2013
Striatal dopamine D1-like receptor binding is unchanged in primary focal dystonia.. 28:2002-6. 2013
Common data elements for clinical research in Friedreich's ataxia.. 28:190-5. 2012
Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.. 27:1513-21. 2012
New synaptic and molecular targets for neuroprotection in Parkinson's disease.. 28:51-60. 2012
A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial.. 27:1026-33. 2012
Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women.. 27:980-7. 2012
Caffeine and risk of Parkinson's disease in a large cohort of men and women.. 27:1276-82. 2012
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.. 27:1392-7. 2012
Oromandibular and lingual dystonia associated with spinocerebellar ataxia type 8.. 27:1741-2. 2012
Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study.. 26:2283-6. 2011
Obesity, diabetes, and risk of Parkinson's disease.. 26:2253-9. 2011
Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".. 26:1864-8. 2011
Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia.. 25:687-95. 2010
Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.. 25:426-32. 2010
Clinical measures of dysarthria in Friedreich Ataxia.. 25:108-11. 2010
Amyloid imaging of Lewy body-associated disorders.. 25:2516-23. 2010
Calcium channel blocker use and risk of Parkinson's disease.. 25:1818-22. 2010
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.. 25:1801-8. 2010
Prenatal and early life factors and risk of Parkinson's disease.. 25:1560-7. 2010
Restless legs syndrome and Parkinson's disease in men.. 25:2654-7. 2010
The role of parkin in familial and sporadic Parkinson's disease.. 25 Suppl 1:S32-9. 2010
Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS.. 24:1820-8. 2009
Transient exacerbation of ataxia with smoking: a prevalence survey.. 24:937-8. 2009
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.. 24:2370-8. 2009
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.. 24:2081-90. 2009
Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease.. 24:1359-65. 2009
Urinary isoprostanes in Friedreich ataxia: lack of correlation with disease features.. 23:1920-2. 2008
Ataxia and cerebellar atrophy--a novel manifestation of neuro-Behçet disease?. 23:307-8. 2008
Perceived imbalance and risk of Parkinson's disease.. 23:613-6. 2008
Recreational physical activity and risk of Parkinson's disease.. 23:69-74. 2008
Telomere length and risk of Parkinson's disease.. 23:302-5. 2008
Survival of Parkinson's disease patients in a large prospective cohort of male health professionals.. 21:1002-7. 2006
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients.. 20:1191-4. 2005
Performance measures in Friedreich ataxia: potential utility as clinical outcome tools.. 20:777-82. 2005
Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.. 19:60-7. 2004
Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease.. 18:804-12. 2003
Prospective study of phobic anxiety and risk of Parkinson's disease.. 18:646-51. 2003
Memory and executive function impairment predict dementia in Parkinson's disease.. 17:1221-6. 2002
Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study.. 17:250-7. 2002